Diversified Healthcare Trust (DHC) Stock Price & Analysis
Diversified Healthcare Trust (DHC) closed at USD 7.87 on Thursday, October 22, 2026, up 2.34% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 7.69; the Oct 22, 2026 session ranged USD 7.65–7.91 on volume of 1,718,839 shares. Market capitalization is $1.91B, with a 52-week range of USD 3.92–9.66 (NMS). Source: Nexqual, retrieved October 23, 2026 at 11:03 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DHC.md
Key facts (DHC)
- Last four reported quarters (through Jun 30, 2026): revenue $1.50B, net income -$266M (-17.7% margin), free cash flow -$155M (SEC filings).
- Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 10.15 (range 8–11.5).
- Total return with dividends: 1Y +84.5% vs S&P 500 +14.9%; 5Y +130.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD -0.13, revenue estimate $369M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DHC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.38B | $1.28B | $1.41B | $1.50B | $1.54B | $1.50B |
| Net income | $175M | -$15.8M | -$294M | -$370M | -$286M | -$266M |
| EPS (diluted) | $0.73 | -$0.07 | -$1.23 | -$1.55 | -$1.19 | — |
| Free cash flow | -$291M | -$340M | -$225M | -$89.5M | -$166M | -$155M |
| Net margin | 12.6% | -1.2% | -20.8% | -24.8% | -18.6% | -17.7% |
| Revenue growth | -15.2% | -7.2% | +9.9% | +6.0% | +2.8% | — |
| Cash + short-term investments | $635M | $658M | $246M | $145M | $105M | — |
| Total debt | — | — | — | $3.05B | $2.44B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DHC)
P/S 1.3x · EV/Sales 2.8x · P/B 1.2x · FCF yield -8.13% · Earnings yield -13.96% · Dividend yield (paid, TTM) 0.51% · Buyback yield (TTM) 0.06% · Net debt $2.33B · EV $4.23B
Analysts (DHC)
Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 10.15 (low 8, high 11.5).
Total return (dividends reinvested) (DHC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +84.5% | +130.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +84.9% | +18.1% |
| Volatility (annualized) | 38.2% | 71.6% |
| Max drawdown | -23.4% (Jul 2026→Oct 2026) | -82.2% (Oct 2021→Dec 2022) |
DHC revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| SHOP | $317.9M | 87.0% | -2.9% |
| Medical Office and Life Science Portfolio | $40.1M | 11.0% | -16.5% |
| Total revenue | $365.4M | 100% | — |
DHC revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Residents fees and services | $317.9M | 87.0% | -2.9% |
| Rental income | $47.5M | 13.0% | -14.0% |
| Total revenue | $365.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DHC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | The RMR Group | “In addition, RMR provides management services to joint ventures, including our existing joint ventures.” |
Quoted from the company's 10-K filed Feb 24, 2026.
DHC company outlook (results filed Aug 3, 2026)
- “Newton, MA (August 3, 2026): Diversified Healthcare Trust (Nasdaq: DHC) today announced its financial results for the quarter ended June 30, 2026, and provided updated full year 2026 financial guidance, which can be found at the Quarterly Reports section of DHC's website at https://www.dhcreit.com/investors/financial-information/quarterly/default.aspx.”
- “The updated full year 2026 financial guidance is consistent with DHC's news release issued on June 1, 2026.”
Quoted word-for-word from the SEC 8-K results press release.
DHC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $-0.16 | -18.8% | $368.7M | 1 |
| Next quarter (ends Dec 2026) | $-0.13 | $-0.15 | -13.3% | $373.2M | 1 |
| Current fiscal year (ends Dec 2026) | $-0.63 | $-0.59 | +7.4% | $1.47B | 3 |
| Next fiscal year (ends Dec 2027) | $-0.43 | $-0.47 | -6.5% | $1.56B | 2 |
DHC options: expected move
Options price a move of about ±12.7% (±$1.01) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±6.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 63.7% | ±12.7% |
| Dec 18, 2026 | 56 | 39.2% | ±10.3% |
| Mar 19, 2027 | 147 | 46.7% | ±27.6% |
30-day implied volatility 50.4% vs 26.7% realized over the last 30 trading days. Put/call ratio (volume) 2. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 11:03 UTC)
| Price | USD 7.87 |
|---|---|
| Change | ▲ 2.34% (up) |
| Previous Close | USD 7.69 |
| Open | USD 7.74 |
| Day Range | USD 7.65 – 7.91 |
| 52-Week Range | USD 3.92 – 9.66 |
| Volume | 1,718,839 shares |
| Market Cap | $1.91B |
| Exchange | NMS |
Technical Analysis (DHC)
Nexqual's technical model rates DHC "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 11:03 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 58.82 (neutral) |
| vs SMA50 | Above (USD 7.81) |
| MACD | -0.07 (negative) |
Analyst Ratings (DHC)
Wall Street analysts rate DHC "Buy" based on 5 analysts, with a mean price target of USD 10.15 (range USD 8–11.5), per Nexqual as of October 23, 2026 at 11:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 10.15 |
| High Target | USD 11.5 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (DHC)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $368.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.1 vs est -0.16 ▲ beat |
| 2026-03-31 | USD -0.13 vs est -0.16 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.22 vs est -0.23 ▲ beat |
Source: Nexqual, October 23, 2026 at 11:03 UTC.
Financials & Fundamentals (DHC)
| Total Revenue | $1.50B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -4.50% |
| Gross Margin | +18.61% |
| Operating Margin | -0.14% |
| Profit Margin | -17.73% |
| ROE | -15.47% |
| Debt / Equity | 1.53 |
| Current Ratio | 6.65 |
| Total Cash | $116.85M |
| Total Debt | $2.42B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$155.01M (-10.3% of revenue) |
Source: Nexqual, October 23, 2026 at 11:03 UTC.
Financial Health Score (DHC)
Nexqual rates Diversified Healthcare Trust's overall financial health "Weak" across five dimensions, as of October 23, 2026 at 11:03 UTC.
| Growth | Mixed — Revenue +2.8% YoY (annual), slow |
|---|---|
| Profitability | Weak — Gross margin 19%, operating -0% (last 12 months) |
| Balance Sheet | Weak — $117M cash and investments vs $2.44B debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$155M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -15%, ROA -0.4% |
Ownership (DHC)
| Insider Ownership | +10.38% |
|---|---|
| Institutional Ownership | +86.13% |
| Shares Outstanding | 242.13M |
| Float | 201.60M |
| Short % of Float | +5.37% |
Source: Nexqual, October 23, 2026 at 11:03 UTC.
Leadership (DHC)
Diversified Healthcare Trust is led by Christopher J. Bilotto, President, CEO & Managing Trustee, per Nexqual as of October 23, 2026 at 11:03 UTC.
| President, CEO & Managing Trustee | Christopher J. Bilotto |
|---|---|
| CFO & Treasurer | Matthew C. Brown |
| Director of Acquisition | David M. Blackman |
Major Backers & Investors (DHC)
Notable institutional backers of Diversified Healthcare Trust include Flat Footed LLC, Silver Point Capital L.p., H/2 Credit Manager, LP, according to Nexqual as of October 23, 2026 at 11:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Flat Footed LLC | 9.7% |
| Silver Point Capital L.p. | 6.4% |
| H/2 Credit Manager, LP | 5.29% |
| Davidson Kempner Capital Management LP | 2.65% |
| Nomura Holdings Inc. | 2.59% |
| Charles Schwab | 1.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.53% |
| Vanguard Group | 8.37% |
| State Street | 3.72% |
| Geode Capital | 2.92% |
Source: Nexqual, October 23, 2026 at 11:03 UTC.
From Diversified Healthcare Trust's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Our management agreements with third party managers generally include provisions that allow us to terminate the agreements under certain circumstances, including if a community does not meet specified financial performance thresholds after a stabilization period.
Legal & Regulatory Risks (Item 1A, quoted)
- We are exposed to operational risks, liabilities and claims with respect to our SHOP segment that could adversely affect our revenues and operations.
- Our managers or other operators may fail to comply with laws relating to the operation of our senior living communities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MPT | Medical Properties Trust, Inc. | USD 2.71 | ▲ 3.04% |
| LTC | LTC Properties, Inc. | USD 43.33 | ▲ 2.7% |
| NHI | National Health Investors, Inc. | USD 66.96 | ▲ 3.14% |
| SBRA | Sabra Health Care REIT, Inc. | USD 19.6 | ▲ 3.7% |
| HR | Healthcare Realty Trust Incorpo | USD 17.93 | ▲ 4% |
| UHT | Universal Health Realty Income | USD 37.81 | ▲ 2.41% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:03 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt